In this virtual roundtable, experts explore the uses of nuclear magnetic resonance (NMR) in the analysis of biologics and biosimilars and discuss how recent advances are changing the game.
High-resolution nuclear magnetic resonance (NMR) is a key technology that provides critical information about protein structure and dynamics. However, its application for the characterisation of biotherapeutic drugs in the pharmaceutical industry has been limited by it being difficult to use, expensive, size limited and to requiring labelled molecules, which all lead to lengthy studies.
In this virtual roundtable our experts discussed how recent advances in acquisition and analysis have changed the situation and now allow for the visualisation of whole antibodies at natural abundance. Thus, making NMR ideally suited for similarity assessment of biologics and biosimilars, as well as enabling evaluation of the structure of therapeutic drugs, without modification, in physiologically relevant conditions.
Scott Bradley (Principal Research Scientist, Eli Lilly and Company), Joan Malmstrøm (Principal Scientist, Novo Nordisk) and Kelly Sackett (Principal Scientist, Pfizer) also explained how, because of its intrinsically high information content, NMR has the potential to reduce the number of techniques needed to characterise therapeutic drugs, thereby saving time and reducing costs.
They also reviewed the current applications of magnetic resonance for the analysis of biotherapeutic drugs, including NMR, electron paramagnetic resonance (EPR) and time domain nuclear magnetic resonance (TD-NMR).
Scott Bradley, PhD
Principal Research Scientist Eli Lilly and Company
Dr. Joan Malmstrøm
CMC Analytical Support, R&D, Novo Nordisk A/S, Måløv, Denmark
Principal Scientist, Pfizer